Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIM-CD: ABBV-154 in Moderately to Severely Active Crohn's Disease
jRCT2051210135Suspended
- Sponsor
- AbbVie Inc.
- Start
- Mar 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Randomised, double-blind trial of ABBV-154 in Crohn's disease (10 arms), sponsored by AbbVie Inc. Primary endpoint: Endoscopic response at Week 12 (Induction). Started Mar 2022; status: suspended.
02
Drugs
ABBV-154
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on jRCT2051210135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210135.